03/11/22

Histologic Evaluation Using the Robarts Histopathology Index in Patients With Ulcerative Colitis in Deep Remission and the Association of Histologic Remission With Risk of Relapse

Jin Park, MD, Soo Jin Kang, MD, Hyuk Yoon, MD, PhD, Jihye Park, MD, PhD, Hyeon Jeong Oh, MD, PhD, Hee young Na, MD, PhD, Hye Seung Lee, MD, PhD, Cheol Min Shin, MD, PhD, Young Soo Park, MD, MS,…
03/11/22

Does Disease Activity After Induction Treatment With Biologics Predict Short-Term Outcome in Crohn’s Disease and Ulcerative Colitis?

Michael Due Larsen, PhD, MSc Pharm, Bente Mertz Nørgård, PhD, MD, Jens Kjeldsen, PhD, MD Inflammatory Bowel Diseases, Volume 28, Issue 11, November 2022, Pages 1658–1666, https://doi.org/10.1093/ibd/izab331 Abstract BackgroundSecondary loss of response to biological therapy is a challenge when treating…
03/11/22

Diagnostic Performance of Magnetic Resonance Enterography Disease Activity Indices Compared with a Histological Reference Standard for Adult Terminal Ileal Crohn’s Disease: Experience from the METRIC Trial

Shankar Kumar, Thomas Parry, Sue Mallett, Gauraang Bhatnagar, Andrew Plumb, Shaun Walsh, Nigel Scott, Ruchi Tandon, Heung Chong, John du Parcq ... Journal of Crohn's and Colitis, Volume 16, Issue 10, October 2022, Pages 1531–1539, https://doi.org/10.1093/ecco-jcc/jjac062 Abstract Background and AimsThe…
03/11/22

Immunomodulator Withdrawal From Anti-TNF Therapy Is Not Associated With Loss of Response in Inflammatory Bowel Disease

Remi Mahmoud,* ,a Hans-Paul Schultheiss,* ,a Jonas Louwers,* Michiel van der Kaaij,* Boris van Hellemondt,* Nofel Mahmmod,‡ Petra van Boeckel,‡ Bindia Jharap,§ Herma Fidder,* ,b and Bas Oldenburg* Clin Gastroenterol Hepatol 2022 Nov;20(11):2577-2587.e6. DOI: 10.1016/j.cgh.2022.01.019 Epub 2022 Jan 31. AbstractBackground…
30/09/22

Proactive Therapeutic Drug Monitoring Versus Conventional Management for Inflammatory Bowel Diseases: A Systematic Review and Meta-Analysis

Nghia H. Nguyen, Virginia Solitano, Sudheer K. Vuyyuru, John K. MacDonald, Silje W. Syversen, Kristin Kaasen Jørgensen, Eileen Crowley, Christopher Ma, Vipul Jairath, Siddharth Singhhttps://doi.org/10.1053/j.gastro.2022.06.052Get rights and content Referred to byCME Exam 3: Proactive Therapeutic Drug Monitoring Versus Conventional Management…
30/09/22

Efficacy and Safety of Elective Switching from Intravenous to Subcutaneous Infliximab [CT-P13]: A Multicentre Cohort Study 

Philip J Smith, Lisa Critchley, Daniel Storey, Belle Gregg, June Stenson, Andrew Kneebone, Tracy Rimmer, Stevena Burke, Shamas Hussain, Wan Yi Teoh ... Show moreJournal of Crohn's and Colitis, Volume 16, Issue 9, September 2022, Pages 1436–1446, https://doi.org/10.1093/ecco-jcc/jjac053 Abstract BackgroundIntravenous…
30/09/22

Predictors of Sustained Response With Tofacitinib Therapy in Patients With Ulcerative Colitis 

William J Sandborn, MD, Alessandro Armuzzi, MD, Giuseppina Liguori, MD, Peter M Irving, MD, Ala I Sharara, MD, Rajiv Mundayat, MSc, Nervin Lawendy, PharmD, John C Woolcott, PhD, Silvio Danese, MDInflammatory Bowel Diseases, Volume 28, Issue 9, September 2022, Pages…
18/07/22

Risk of Immunomediated Adverse Events and Loss of Response to Infliximab in Elderly Patients with Inflammatory Bowel Disease: A Cohort Study of the ENEIDA Registry

Margalida Calafat, Míriam Mañosa, Elena Ricart et al Journal of Crohn's and Colitis, Volume 16, Issue 6, June 2022, Pages 946–953 ABSTRACT Background and Aims Immunomediated adverse events [IAEs] are the most frequently reported infliximab [IFX]-related adverse events. Combination therapy…
18/07/22

Transitioning from Intravenous to Subcutaneous Vedolizumab in Patients with Inflammatory Bowel Disease [TRAVELESS]

Esther Ventress, David Young, Sohail Rahmany et al Journal of Crohn's and Colitis, Volume 16, Issue 6, June 2022, Pages 911–921 ABSTRACT Background and Aims Subcutaneous [SC] vedolizumab presents the opportunity for inflammatory bowel disease [IBD] patients to manage their…
15/07/22

Systematic review with meta-analysis: the effectiveness of either ustekinumab or vedolizumab in patients with Crohn's disease refractory to anti-tumour necrosis factor

Laurène Parrot,Catherine Dong,Franck Carbonnel,Antoine Meyer First published: 01 December 2021 https://doi.org/10.1111/apt.16714 Summary Background Ustekinumab and vedolizumab are commonly used after anti-tumour necrosis factor (TNF) failure in patients with Crohn’s disease (CD). No randomised controlled trial has compared these drugs. Aims…
15/07/22

Natural History and Risk Stratification of Recurrent Crohn's Disease After Ileocolonic Resection: A Multicenter Retrospective Cohort Study

Vincent Joustra 1, Marjolijn Duijvestein 1, Aart Mookhoek 2, Willem Bemelman 3, Christianne Buskens 3, Matic Koželj 4, Gregor Novak 4, Pieter Hindryckx 5, Nahid Mostafavi 6, Geert D'Haens 1 Affiliations PMID: 33783507 PMCID: PMC8730683 DOI: 10.1093/ibd/izab044 Free PMC article…